Comparison of GP and NP Regimen in Treatment of Advanced Non2small Cell Lung Cancer

Objective 　To evaluate and compare the efficacy and toxicity between combination of gemcit2 abine and cisplatin ( GP) and combination of navelbine and cisplatin (NP) in the t reatment of patient s with advanced non - small cell lung cancer (NSCLC) . Methods 　Eighty patient s with locally advanced or me2 tastatic NSCLC were enrolled into the study, with 41 patient s in GP group and 39 in NP group . Patient s ' characteristics were similar between the two groups. They were given gemcitabine 1 000 mg/ m2, or na2 velbine 25 mg/ m2 on days 1 and 8, and cisplatin 30 mg/ m2 on days 1～3. The chemotherapy was repeat2 ed every 3 weeks as a cycle. Results 　An objective response rate of 41. 5 % was observed in GP arm ver2 sus 38. 5 % in NP arm ( P > 0. 05) . The 12year survival rate was 36. 6 % in GP compared to 35. 9 % in NP ( P > 0. 05) . The median survival duration was 9. 4 months for GP arm and 8. 9 months for NP arm. My2 elosuppression was the major dose2limiting toxicity. The incidence of grade Ⅲ/ Ⅳleukopenia was signifi2 cantly higher in the NP group than that in GP group ( P < 0. 05), while grade Ⅲ/ Ⅳ thrombocytopenia occurred more f requently in the GP group than that in NP group ( P < 0. 05) . Conclusion 　The GP combi2 nation is as equally active and well tolerated as the NP combination in the t reatment of patient s with ad2 vanced NSCLC.